Regulation - Pharmaceutical

Filter

Current filters:

Pharmaceutical

Popular Filters

46 to 70 of 7197 results

Executive Q&A: Bob Radie, chief executive and president of Egalet

Executive Q&A: Bob Radie, chief executive and president of Egalet

11-04-2014

In an interview with The Pharma Letter, Egalet Corporation’s chief executive Bob Radie discusses the…

AnalgesiaChemistryChief executiveCombination productsEgalet CorpEgalet CorporationInterviewsPharmaceuticalSevere chronic painUSA

Chugai files NDA for vemurafenib for melanoma

Chugai files NDA for vemurafenib for melanoma

11-04-2014

Japanese drugmaker Chugai Pharmaceutical has filed a new drug application to the Ministry of Health,…

BRAFV600ChemistryChugai PharmaceuticalJapanJO28178OncologyOrganochloridesPharmaceuticalRegulationRoche Diagnosticsvemurafenib

UAE’s Julphar inks five-year deal to market Merck & Co drugs

11-04-2014

United Arab Emirates-based drugmaker Julphar has signed a five-year licensing deal with US pharma giant…

JulpharLicensingMerck & CoPharmaceutical

RAPS Taiwan Chapter becomes first in Asia

11-04-2014

The Regulatory Affairs Professionals Society (RAPS) has announced the establishment of a new chapter…

Asia-PacificMarkets & MarketingPharmaceuticalRegulation

European Commission specifies post-authorization efficacy study guidelines

European Commission specifies post-authorization efficacy study guidelines

11-04-2014

The European Commission has adopted a delegated act specifying the situations where a post-authorization…

EuropeEuropean Medicines AgencyEuropean UnionPharmaceuticalPharmaceutical industryPharmaceutical sciencesPharmacologyRegulationResearch

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

Potential growth trajectories for the US biopharmaceutical sector

Potential growth trajectories for the US biopharmaceutical sector

11-04-2014

The Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday released a report that outlines…

North AmericaPharmaceuticalPoliticsResearchUSA

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

10-04-2014

US pharma major Bristol-Myers Squibb has presented new Phase III trial data of its combination therapy…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalResearch

Promising results for Merck & Co’s hepatitis C drug combo

Promising results for Merck & Co’s hepatitis C drug combo

10-04-2014

US pharma giant Merck & Co has announced additional data from the ongoing C-WORTHy study, a multi-arm…

Anti-viralsMerck & CoMK-5172PharmaceuticalResearch

Joint purchasing of vaccines and medicines becomes a reality in the EU

Joint purchasing of vaccines and medicines becomes a reality in the EU

10-04-2014

The European Commission today approved a Joint Procurement Agreement, which will enable all European…

Antibiotics and Infectious diseasesEuropeFinancialMarkets & MarketingPharmaceuticalVaccines

Australia to review program for life-saving drugs access

Australia to review program for life-saving drugs access

10-04-2014

The Australian government says that it will review the Life Saving Drugs Program (LSDP) - a move aimed…

Asia-PacificAustraliaFinancialHealthcarePharmaceuticalRare diseases

Decline in global pharma industry sales force levels

10-04-2014

Cegedim Strategic Data, a global provider of health care research data and services, reports that there…

GlobalManagementPharmaceutical

Erytech adds a new product candidate to its development portfolio

10-04-2014

French cancer focused drug developer Erytech Pharma has added a new product development candidate, ERY-MET,…

ERY-METErytech PharmaOncologyPharmaceuticalResearch

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

FDA clinical hold on Halozyme’s PEGPH20 pancreatic cancer trial

FDA clinical hold on Halozyme’s PEGPH20 pancreatic cancer trial

09-04-2014

US biopharma firm Halozyme Therapeutics says that the US Food and Drug Administration informed the company…

Halozyme TherapeuticsNorth AmericaOncologyPharmaceuticalRegulationResearchUSA

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

09-04-2014

US drugmaker Forest Laboratories and partner Almirall, Spain’s largest pharma company, say they have…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryUSA

JPMA sanctions against Takeda over promotional activities for candesartan in Japan

09-04-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it has received notice of sanctions imposed by…

Asia-PacificBlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalTakeda Pharmaceuticals

Need for age-appropriate drug formulations for elderly; report

Need for age-appropriate drug formulations for elderly; report

09-04-2014

Despite the elderly being the fastest-growing segment of the global population, only a few of their treatments…

GlobalHealthcarePharmaceuticalResearch

46 to 70 of 7197 results

Back to top